Macroautophagy (hereafter referred to as autophagy) is a bulk intracellular degradation process that involves the formation of double-membraned vesicles called autophagosomes that engulf cytoplasmic components and deliver them to lysosomes for degradation[@klionsky2012]. Unlike chaperone-mediated [autophagy](/entities/autophagy) (CMA), which selectively degrades individual proteins bearing specific motifs, macroautophagy can engulf large organelles, protein aggregates, and portions of the cytoplasm in a relatively non-selective manner, though selective forms also exist[@johansen2011].
Macroautophagy (hereafter referred to as autophagy) is a bulk intracellular degradation process that involves the formation of double-membraned vesicles called autophagosomes that engulf cytoplasmic components and deliver them to lysosomes for degradation[@klionsky2012]. Unlike chaperone-mediated [autophagy](/entities/autophagy) (CMA), which selectively degrades individual proteins bearing specific motifs, macroautophagy can engulf large organelles, protein aggregates, and portions of the cytoplasm in a relatively non-selective manner, though selective forms also exist[@johansen2011].
Macroautophagy is the most studied form of autophagy and serves as a critical quality control mechanism in all eukaryotic cells. In post-mitotic [neurons](/entities/neurons), which cannot dilute damaged proteins and organelles through cell division, macroautophagy is especially crucial for maintaining proteostasis[@nixon2013]. The process was first described by Christian de Duve in the 1960s, and the term derives from the Greek words for "self-eating"[@klionsky2012].
The autophagy-lysosomal pathway (ALP) comprises the entire cascade from autophagosome biogenesis through lysosomal fusion and degradation. Dysfunction at any step of this pathway contributes to the accumulation of toxic protein aggregates and damaged organelles—hallmarks of neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[@menzies2017].
Autophagy initiation is regulated by the ULK1 (Unc-51 Like Autophagy Activating Kinase 1) complex, which includes ULK1, ATG13, FIP200, and ATG101[@egan2011]. This complex is regulated by [mTOR](/mechanisms/mtor-signaling-pathway) (mechanistic Target of Rapamycin) and AMPK (AMP-activated protein kinase)—nutrient and energy sensors, respectively. Under nutrient-rich conditions, mTOR phosphorylates and inhibits the ULK1 complex. Upon nutrient deprivation or stress, mTOR inhibition releases this brake, allowing autophagy to proceed[@egan2011].
The VPS34 (Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3) complex, centered around Beclin-1 (BECN1), generates phosphatidylinositol 3-phosphate (PI3P) on isolation membranes[@he2010]. This lipid signaling recruits downstream autophagy proteins to the forming autophagosome. Beclin-1 is frequently compromised in neurodegenerative diseases, making this step critical for neuronal survival[@he2010].
Two ubiquitin-like conjugation systems drive autophagosome expansion:
LC3-II serves as both a scaffold for cargo recruitment and a marker for autophagosome identification. The cargo receptor proteins (e.g., p62/SQSTM1, OPTN, NDP52) bind ubiquitinated cargo and LC3-II, bridging selective autophagy substrates to the forming autophagosome[@johansen2011].
Mature autophagosomes fuse with lysosomes to form autolysosomes. This fusion requires the SNARE complex (VAMP8, SNAP-29, STX17), HOPS complex, and lysosomal membrane proteins including LAMP-1 and LAMP-2[@eskelinen2005]. The LAMP-2 isoform LAMP-2A is particularly important for chaperone-mediated autophagy, while LAMP-2B supports macroautophagy fusion events[@eskelinen2005].
Once fused, lysosomal hydrolases (cathepsins) degrade the autophagosomal contents. The resulting amino acids, lipids, and nucleotides are recycled back to the cytoplasm for reuse in biosynthesis and energy production[@klionsky2012].
In Alzheimer's disease, macroautophagy is severely impaired at multiple stages. Autophagosomes accumulate in dystrophic neurites surrounding [amyloid-beta](/proteins/amyloid-beta) plaques, indicating a blockade in autophagosome-lysosome fusion[@nixon2005]. This accumulation of incompletely degraded material contributes to neuronal toxicity. The [amyloid precursor protein](/entities/app-protein) (APP) and its processing enzymes are regulated by autophagy, and impaired autophagy accelerates amyloid-beta accumulation[@nixon2005].
The [tau protein](/proteins/tau), which forms neurofibrillary tangles in AD, is degraded by both macroautophagy and the proteasome. Hyperphosphorylated tau accumulates when autophagy is impaired, creating a vicious cycle of tau aggregation and autophagy dysfunction[@wang2016].
Parkinson's disease is characterized by the accumulation of damaged mitochondria (mitophagy defects) and [alpha-synuclein](/proteins/alpha-synuclein) aggregates. Macroautophagy helps clear pathogenic alpha-synuclein aggregates, and impaired autophagy contributes to their accumulation[@lashuel2002]. Mutations in genes linked to familial PD, including PINK1 and PARKIN, disrupt mitophagy—a specialized form of macroautophagy that selectively removes damaged mitochondria[@lashuel2002].
The SNCA (alpha-synuclein) gene mutations that cause familial PD impair autophagy at multiple points, and exogenously added alpha-synuclein oligomers can inhibit macroautophagy, suggesting a bidirectional relationship between protein aggregation and autophagy failure[@lashuel2002].
ALS-associated mutations in genes including SOD1, [TDP-43](/mechanisms/tdp-43-proteinopathy), FUS, and [C9orf72](/entities/c9orf72) affect autophagy function. Autophagosomes accumulate in motor neurons of ALS patients, indicating a fusion or degradation defect[@liu2016]. The C9orf72 repeat expansion, the most common genetic cause of ALS, regulates autophagy through interaction with the ULK1 complex and SMCR8[@liu2016].
| Protein/Gene | Function | Neurodegeneration Relevance |
|--------------|----------|----------------------------|
| ULK1 | Kinase complex initiating autophagy | Regulated by mTOR; AMPK activates in stress |
| Beclin-1 (BECN1) | PI3K complex, initiates nucleation | Reduced in AD brains; heterozygous deletion promotes neurodegeneration |
| ATG5, ATG7 | Ubiquitin-like conjugation systems | Essential for autophagosome formation |
| LC3 (MAP1LC3A/B) | Autophagosome marker | LC3-II levels indicate autophagy flux |
| p62 (SQSTM1) | Selective autophagy receptor | Accumulates when autophagy impaired; mutations cause ALS/FTD |
| mTOR | Master regulator of autophagy | Hyperactive mTOR inhibits autophagy in AD |
| AMPK | Energy sensor, activates autophagy | Activated in energy-deprived neurons |
Rapamycin and its analogs (rapalogs) inhibit mTOR and induce autophagy. While these compounds enhance autophagy in animal models, their immunosuppressant effects and potential for non-selective autophagy activation complicate clinical translation[@bove2011].
Several small molecules are being investigated to enhance autophagy in neurodegeneration:
Viral vector delivery of autophagy-related genes (e.g., BECN1, ATG5, TFEB) is being explored to enhance autophagy in targeted brain regions[@decressac2010]. [TFEB](/entities/tfeb) (Transcription Factor EB) overexpression potently activates the entire autophagy-lysosomal pathway and has shown promise in animal models of AD and PD[@decressac2010].
Macroautophagy operates alongside other autophagy pathways: